IP Library Granted Patent US 12,133,893
Granted Patent B2
US 12,133,893 · App. 17/410,554 · Granted Nov 5, 2024

In-situ stable injectable collagen-based hydrogels for cell and growth factor delivery

Inventors: Yunzhi Yang (Stanford, CA); Seyedsina Moeinzadeh (Mountain View, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K47/42A61K9/0019A61K9/06A61K35/28A61K47/02A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,133,893
App. No.
17/410,554
Granted
Nov 5, 2024
Kind
B2
Abstract

A stable injectable collagen-based hydrogel delivery platform and method is provided to obtain the viscosity, post-injection stability and mechanical properties needed of an injectable collagen matrix via incorporating alginate and calcium sulfate (CaSO 4 ) into the matrix. The hydrogel (Alg/Col hydrogel) is shear-thinning, injectable through commercially available needles and stable right after injection.

Claims (8)

1. A delivery platform kit for cells or therapeutics, wherein the delivery platform kit comprises a first liquid container and a second liquid container, comprising:

(a) the first liquid container in the delivery platform kit comprising a first liquid, wherein the first liquid is an alginate precursor liquid stored at a temperature of about 4° C., wherein the alginate precursor liquid is dissolved in a calcium free medium and a basic pH medium, and wherein the calcium free medium is defined as without calcium salts and Ca 2+ ions; and

(b) the second liquid container in the delivery platform kit comprising a second liquid, wherein the second liquid is a collagen and CaSO 4 precursor liquid stored at a temperature of about 4° C., wherein the collagen and CaSO 4 precursor liquid is dissolved in a calcium free medium and an acidic medium, wherein the calcium free medium is defined as without calcium salts or Ca 2+ ions.

2. The delivery platform as set forth in claim 1 , wherein the calcium free and basic pH medium is defined as a pH higher than physiological pH (7.4).

3. The delivery platform as set forth in claim 1 , wherein the calcium free and acidic medium is defined as a pH lower than physiological pH (7.4).

4. The delivery platform as set forth in claim 1 , wherein the first liquid container, the second liquid container, or both further comprising cells, therapeutics, or a combination thereof.

5. The delivery platform as set forth in claim 1 , wherein the supplemented CaSO 4 is in the range of 1-10 mg/mL.

6. The delivery platform as set forth in claim 1 , wherein the alginate in the alginate precursor liquid in the first liquid container and the collagen in the collagen and CaSO 4 precursor liquid in the second liquid container have a weight ratio ranging from 1/10 to 10/1.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 25, 2024
From: STANFORD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 066371/0066 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2021
From: YANG, YUNZHI; MOEINZADEH, SEYEDSINA
To: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
Reel/Frame 057331/0432 →
Continuity (2)
Provisional Application 63069347 · Aug 24, 2020
Related Publication 20220054639A1 · Feb 24, 2022